

PRESS RELEASE

Munich, Germany, 21st of March 2019 – **FCF Fox Corporate Finance strengthens its Life Science Advisory Board with the appointment of Dr. Alexandra Goll and Prof. Dr. Horst Domdey**

FCF Fox Corporate Finance ("FCF") is pleased to announce the appointment of two further renowned experts to its Life Science Advisory Board. From now on, Dr. Alexandra Goll and Prof. Dr. Horst Domdey will support and advise the financing specialist as part of the Life Science advisory board.

Dr. Alexandra Goll is an industry specialist with extensive experience across the entire value chain of biopharmaceutical research, development and investment. Dr. Goll is managing director of BioPharma Advisory, a strategy advisory firm specialized on innovative companies in Biotechnology, Med-Tech and Pharma. Her experiences range from acting as Global Business Leader for HIV and CMV at Hoffmann-La Roche to serving as General Partner at TVM Capital GmbH. With TVM, Dr. Goll was involved in fundraising activities for TVM Capital GmbH and TVM Life Sciences and was, among others, an early investor in Actelion Pharmaceuticals Ltd. and Pharmasset, Inc.. Alexandra was elected into the top 40 of most successful private equity females in Europe by Private Equity News in 2008. Commenting on the announcement, Dr. Goll stated, "It is a pleasure to join the FCF Life Science Advisory Board, complementing and supporting the life science activities of FCF. I am looking forward to contributing my industry know-how to FCF."

Since more than 20 years, Prof. Dr. Horst Domdey is the key person of the business-oriented life science activities in the greater Munich area. As Managing Director of Bio^M Biotech Cluster Development GmbH he oversees all ongoing local and regional activities in biotech, med-tech and health-tech. His excellent network with hundreds of local and international scientists enables him to identify upcoming innovations very early. He is the first contact for life science entrepreneurs who intend to start their own company and he has accompanied in this role more than 100 start-ups in their realisation process. More than 40 of those received a seed investment through Bio^M AG, Bio^M's finance arm. He has extensive knowledge of company start-ups, financing and corporate support in all drug and technology development stages. From 2010 to 2015, he supervised the 100 million Euro "m4 - Personalised Medicine" excellence cluster programme, which involved more than 100 biotechnology companies and research institutes. Before joining Bio^M, he held a professorship in biochemistry at the Gene Centre of the LMU Munich. „I am very honoured to join FCF's Life Science Advisory Board and am thrilled to build on previous successes", said Prof. Domdey.

Dr. Mathias Schott, Director of Life Sciences at FCF, is very excited about the new members: "With Dr. Goll and Prof. Dr. Domdey, our board now has two further significant specialists with whom we can further broaden the high level of expertise that we already have in the sophisticated field of life science." Arno Fuchs, CEO of FCF, also sees the latest additions to the Life Science Advisory Board as part of his company's overall strategy: "FCF operates as a financing specialist in segments that are challenging not only in the area of finance, but also at the operating level. With this in mind, we always strive to combine the highest available expertise in these areas within our committee members. The fact that we can welcome Dr. Goll and Prof. Dr. Domdey to the Life Science Advisory Board, clearly shows how consistent we are in implementing this strategy," said Arno Fuchs.

With these appointments, FCF further complements its existing Life Science Advisory Board consisting of Claus Schalper, Serial Entrepreneur with seed to IPO experience, and Dr. Holger Bengs, initiator and organizer of European Chemistry Partnering, the latest conference / initiative for venture and growth companies in the chemical space in Europe.

ABOUT FCF FOX CORPORATE FINANCE

FCF is a specialized Investment Bank and Financing Specialist, advising public and private small/mid-market companies in the German speaking regions.

FCF focuses on four primary client segments:

- **Mid-Markets:** *Medium-sized clients with sustainable business models in typical "Mittelstand" industries, such as automotive supply, communications, industrial machinery, logistics, etc.;*
- **Real-Tech:** *R&D-driven clients with proof-of-concepts in technology sectors, entering the commercialization stage with first revenues;*
- **Growth:** *Fast growing clients in highly innovative markets, that had a successfully market entry and are seeking to expand widely;*
- **Life Sciences:** *Highly innovative clients that have their DNA embedded in developing cutting-edge biotechnology, med-tech, health-tech and pharmaceuticals solutions*

FCF arranges, structures, and places equity and debt capital transactions and supports its clients' growth, IPO/Pre-IPO, acquisition and standard balance sheet (re-)financing strategies at the best available terms.

Founded in 2005 and headquartered in Munich, FCF has direct relationships and works with all leading German, European and international/US financiers, lenders and investment houses addressing German small/mid-cap companies.

Media Contact

FCF Fox Corporate Finance GmbH
T: +49-89-20 60 4090
F: +49-89-20 60 409 -299

Maximilianstrasse 12-14
80539 München
www.fcf.de